Australian Pharmaceutical Industries

Australian Pharmaceutical Industries (API) is an Australian health and beauty company whose activities have centred on pharmaceutical wholesaling, pharmacy retailing and the manufacture or distribution of healthcare products. The company is described as Australia’s largest wholesale distributor of pharmaceuticals and allied products, supplying community pharmacies and institutional healthcare customers while also operating retail and franchise businesses. The business began in 1910 as Chemists’ Co-operative of New South Wales Limited. It subsequently traded as Wholesale Drug Co before adopting the Australian Pharmaceutical Industries name in 1971. Its original cooperative and wholesale orientation remained important as the company expanded beyond traditional pharmacy distribution into medical, surgical, hospital and consumer-health categories. API grew through a series of acquisitions. In 1996 it bought Newmans & Western Pharmaceuticals, followed in 1997 by Amed Supplies Australia, which broadened its medical and surgical coverage for hospital customers. The company became publicly traded on the Australian Securities Exchange on 16 June 1997. It launched the Chemworld Chemist banner in 1998 and acquired the pharmaceutical wholesaling and manufacturing operations of Washington H. Soul Pattinson in 2000. The purchase of Hospital Supplies of Australia in 2001 extended its reach into public and private hospitals. The company also pursued expansion in New Zealand. In 2002 it acquired the Interpacific and Interpharma businesses, including operations associated with pharmacy wholesaling and retailing, over-the-counter pharmaceutical manufacturing and dental-product distribution. API later sold its New Zealand healthcare and logistics pharmacy business in 2005, reflecting a gradual concentration on its Australian pharmacy channel. Retail became a more prominent part of the strategy in the 2000s. In 2004 API acquired the Priceline, Priceline Pharmacy, House and Price Attack retail brands from New Price Retail. The transaction helped shift the company toward an integrated distribution-and-retail model, with Priceline Pharmacy becoming the principal focus. API sold Halas Dental in 2005 and divested House and Price Attack in 2007 as it narrowed its retail emphasis. API subsequently developed a broader health, beauty and pharmacy portfolio. It agreed in 2018 to acquire Clearskincare Clinics, initially taking a majority interest and moving to full ownership by September 2021. Wesfarmers acquired API for A$774 million in March 2022, ending its period as an independently listed company and placing the business within the Wesfarmers group. In November 2023 API acquired Silk Laser Clinics, adding another appearance- and aesthetic-treatment business to its portfolio. The company’s retail health and beauty activities have operated under brands including Soul Pattinson and Pharmacist Advice, while its history is closely associated with Priceline and Priceline Pharmacy. API’s role combines wholesale logistics, pharmacy support, retail and franchise operations, and selected health and beauty services rather than being limited to conventional pharmaceutical manufacturing. Following the Wesfarmers acquisition, API continues as an operating business within a larger Australian diversified group.

Australian Pharmaceutical Industries traces its origins to 1910, when it was incorporated as Chemists’ Co-operative of New South Wales Limited. The enterprise was established around the needs of pharmacy businesses and developed as a wholesale supplier of medicines and allied goods. It later operated under the name Wholesale Drug Co and adopted the Australian Pharmaceutical Industries name in 1971. The company expanded its wholesale base through acquisitions during the 1990s. Newmans & Western Pharmaceuticals was acquired in 1996, and Amed Supplies Australia followed in 1997. The latter transaction strengthened API’s position in medical and surgical supplies and increased its capacity to serve hospital customers. API was listed on the Australian Securities Exchange on 16 June 1997. Retail pharmacy became an increasingly important strategic direction. API introduced the Chemworld Chemist banner in 1998 and acquired the pharmaceutical wholesaling and manufacturing operations of Washington H. Soul Pattinson in 2000. On 29 October 2001, it purchased Hospital Supplies of Australia, previously owned by the Victorian Healthcare Association. This acquisition enabled API to distribute to public and private hospitals as well as community pharmacies. In 2002, API acquired Interpacific and Interpharma in New Zealand. The acquired activities included pharmacy wholesaling and retailing, over-the-counter pharmaceutical manufacturing and dental-product distribution, with businesses including Zuellig Pharma, PSM Healthcare and Halas Dental. API later sold its New Zealand healthcare and logistics pharmacy business on 14 December 2005. It also sold the Halas Dental business in 2005 as part of a more focused pharmacy strategy. A major retail development came on 6 October 2004, when API acquired Priceline, Priceline Pharmacy, House and Price Attack from New Price Retail. The transaction accelerated API’s move toward a retail-led model, particularly through Priceline Pharmacy. In 2005, the company formed a joint venture with ABN AMRO Capital Advisory Australia; the joint venture subsequently acquired Clifford Hallam Pharmaceuticals. In 2007 API divested House and Price Attack, concentrating its retail attention on Priceline. API experienced a significant accounting controversy in 2006. Following the introduction of a new IT system, the company discovered that A$17.2 million of previously declared profit could not be traced. Forensic accountants were unable to locate the missing amount, and API wrote the entire figure off in its annual results, resulting in a reported net loss of A$17.2 million. Chief executive Jeff Sher resigned after a disagreement with the board concerning the strategic handling of the discrepancy. The issue was later understood to have historical relevance predating API’s acquisition of Priceline. The company continued to broaden its health and beauty activities in the late 2010s and 2020s. In 2018 API agreed to acquire Clearskincare Clinics, initially purchasing a 50.1 percent interest and increasing its ownership to 100 percent by the end of September 2021. Wesfarmers acquired API for A$774 million in March 2022, ending API’s independent ASX-listed status. API then acquired Silk Laser Clinics in November 2023. API’s business has therefore evolved from a cooperative pharmaceutical wholesaler into an integrated Australian health and beauty platform. Its activities encompass wholesale distribution, pharmacy retailing, franchise support, consumer health and beauty, and clinic-based skin-care and aesthetic services. Its retail presence has included the Soul Pattinson and Pharmacist Advice brands, while Priceline and Priceline Pharmacy have been central to its modern retail history.

1. 2023Acquisition of Silk Laser Clinics

   API added Silk Laser Clinics to its health and beauty portfolio.

   Source
2. 2022Acquired by Wesfarmers

   Wesfarmers acquired API for A$774 million, ending its independent listed-company status.

   Source
3. 2021Reaches full ownership of Clearskincare Clinics

   API increased its ownership of Clearskincare Clinics to 100 percent by the end of September.

   Source
4. 2018Agreement to acquire Clearskincare Clinics

   API agreed to acquire a majority stake in the skin-care clinic business, later moving to full ownership.

   Source
5. 2007Divestment of House and Price Attack

   API sold the two retail brands to concentrate its strategy on Priceline.

   Source
6. 2004Acquisition of Priceline, Priceline Pharmacy, House and Price Attack

   The retail acquisition accelerated API’s focus on pharmacy-led health and beauty retailing.

   Source
7. 2002Expansion into New Zealand

   API acquired Interpacific and Interpharma businesses involved in pharmacy, consumer pharmaceuticals and dental distribution.

   Source
8. 2001Acquisition of Hospital Supplies of Australia

   The acquisition extended API’s distribution reach to public and private hospitals.

   Source
9. 2000Acquisition of Washington H. Soul Pattinson operations

   API acquired Soul Pattinson’s pharmaceutical wholesaling and manufacturing operations.

   Source
10. 1998Launch of the Chemworld Chemist banner

    API introduced a new retail pharmacy banner group.

    Source
11. 1997Acquisition of Amed Supplies Australia and ASX listing

    Amed broadened medical and surgical supply coverage, and API listed on the Australian Securities Exchange on 16 June.

    Source
12. 1996Acquisition of Newmans & Western Pharmaceuticals

    The acquisition expanded API’s pharmaceutical wholesale operations.

    Source
13. 1971Adopts the Australian Pharmaceutical Industries name

    After operating as Wholesale Drug Co, the company adopted its current name.

    Source
14. 1910Incorporated as Chemists’ Co-operative of New South Wales

    The business was established as a cooperative serving pharmacy and pharmaceutical wholesale needs in New South Wales.

    Source

An integrated Australian pharmacy and health-and-beauty operator combining pharmaceutical wholesaling, pharmacy retail and franchise support with consumer health, skin-care and aesthetic services.

• Pharmaceutical wholesale distributionPharmaceutical distribution

  API’s core business is the wholesale distribution of prescription medicines, over-the-counter products and allied healthcare goods. Its distribution activities support community pharmacies and extend to institutional customers, including public and private hospitals. The business has been enlarged through acquisitions in pharmaceutical, medical, surgical and hospital supply categories.

• Pharmacy retail and franchise operationsPharmacy retail

  API operates and supports pharmacy retail through company-owned stores and franchise arrangements. Its retail history includes Priceline Pharmacy, Soul Pattinson and Pharmacist Advice, with the Priceline Pharmacy model becoming a central part of the company’s retail-led strategy in the 2000s.

• Consumer health and beauty productsHealth and beauty retail

  The company distributes and retails health, beauty and personal-care products alongside medicines. This category reflects API’s expansion beyond traditional pharmaceutical wholesaling and its connection with pharmacy-based consumer retail.

• Clearskincare ClinicsSkin-care clinics2018

  Clearskincare Clinics became part of API through a transaction agreed in 2018. API initially acquired a 50.1 percent interest and increased its ownership to full control by September 2021, adding clinic-based skin-care services to its health and beauty portfolio.

• Silk Laser ClinicsAesthetic treatment clinics2023

  Silk Laser Clinics was acquired by API in November 2023. The business expanded API’s presence in laser and aesthetic treatment services and complemented its existing health, beauty and skin-care activities.

• 2023Acquire Silk Laser ClinicsM&A

  API continued expanding its health and beauty activities after becoming part of Wesfarmers.

  What changed. API acquired the Silk Laser Clinics business.

  Aftermath. The acquisition added laser and aesthetic treatment services to API’s existing pharmacy, skin-care and beauty portfolio.

  Source
• 2022Accept Wesfarmers acquisitionM&A

  API had operated as an ASX-listed Australian pharmaceutical and health-and-beauty company.

  What changed. Wesfarmers acquired API for A$774 million.

  Aftermath. API became part of Wesfarmers and ceased to operate as an independent listed company.

  Acquisition value. A$774 million (March 2022)

  Source
• 2018Acquire Clearskincare ClinicsM&A

  API was broadening its health and beauty activities beyond pharmaceutical distribution and pharmacy retail.

  What changed. API agreed to acquire Clearskincare Clinics, initially taking a 50.1 percent stake and later increasing its ownership to 100 percent.

  Aftermath. Full ownership was reached by the end of September 2021, making the clinic business part of API’s health and beauty portfolio.

  Acquisition consideration. A$127.4 million (2018 acquisition agreement)

  Source
• 2004Build a retail-led pharmacy strategy through the Priceline acquisitionStrategy

  API sought to develop a stronger retail presence alongside its established pharmaceutical distribution business.

  What changed. API acquired Priceline, Priceline Pharmacy, House and Price Attack from New Price Retail.

  Aftermath. The company later sold House and Price Attack and concentrated its retail strategy primarily on Priceline and Priceline Pharmacy.

  Source
• 2002Resists Sigma Pharmaceuticals takeover attemptM&A

  Sigma Pharmaceuticals attempted to acquire API, but the proposal was blocked by the Australian Competition and Consumer Commission.

  What changed. The transaction did not proceed because of competition concerns.

  Aftermath. Sigma later made another approach in 2006, which it withdrew in December of that year.

  • Sigma Pharmaceuticals — Sigma subsequently pursued a second takeover attempt before withdrawing it on 11 December 2006.
  Source

• 2006Unaccounted profit after IT-system implementationControversy

  After a new IT system was implemented, API identified A$17.2 million of declared profit that could not be traced. Forensic accountants did not locate the amount, and the company wrote it off, producing a net loss of A$17.2 million. The episode also contributed to the departure of chief executive Jeff Sher after a disagreement with the board about the treatment of the discrepancy.

  Source
• 2005Priceline employment dispute under WorkChoicesControversy

  Priceline dismissed 32 workers for stated operational reasons during the period of the WorkChoices industrial-relations legislation. A dismissed store-layout planner challenged his termination and alleged that his position had been replaced with a lower-paid role. The Australian Industrial Relations Commission found in Priceline’s favour, concluding that the dismissal resulted from financial difficulties and structural reorganisation.

  Source

• 2023API acquires Silk Laser Clinics

  API acquired the Silk Laser Clinics business, expanding its health-and-beauty portfolio into laser and aesthetic treatment services.

  M&AProduct launch
  Source
• 2022Wesfarmers acquires Australian Pharmaceutical Industries

  Wesfarmers completed its acquisition of API for A$774 million, bringing the pharmaceutical distribution, pharmacy retail and health-and-beauty business into its corporate group.

  M&A
  Source
• 2006Sigma Pharmaceuticals withdraws its renewed takeover bid for API

  Sigma Pharmaceuticals withdrew discussions concerning a second attempt to acquire API on 11 December 2006. Sigma had also attempted to take over API in 2002, but that proposal was blocked by the Australian Competition and Consumer Commission.

  M&ARegulation
  Source

1. Australian Pharmaceutical Industries
2. Australian Pharmaceutical Industries official website